Aerospace and defense company Redwire (NYSE: RDW) missed Wall Street’s revenue expectations in Q2 CY2025, with sales falling 20.9% year on year to $61.76 million. On the other hand, the company’s full-year revenue guidance of $500 million at the midpoint came in 16.5% above analysts’ estimates. Its GAAP loss of $1.41 per share was significantly below analysts’ consensus estimates.

Is now the time to buy RDW? Find out in our full research report (it’s free).

StockStory’s Take

Redwire’s second quarter was marked by a sharp revenue shortfall and a significant loss, prompting a strong negative reaction from the market. Management attributed the underperformance to delayed government contract awards and technical challenges in a major RF systems development project, which led to unfavorable cost adjustments. CEO Peter Cannito acknowledged, “Q2 was a disappointing quarter for adjusted EBITDA compared to our expectations,” and emphasized the outsized impact of a single troubled project on profitability. The team is now focused on addressing operational execution issues and stabilizing its development programs.

Looking forward, Redwire’s updated outlook is shaped by continued integration of the Edge Autonomy acquisition and an expanded focus on both space and defense technology sectors. Management highlighted growth opportunities tied to government and international defense spending, as well as new ventures in microgravity pharmaceutical research through its SpaceMD entity. CFO Jonathan Baliff cautioned that, “uncertainty in the timing of government programs associated with the budgeting process” remains a risk, but the company is positioning itself to benefit as budgetary clarity improves and as production programs ramp up.

Key Insights from Management’s Remarks

Management linked the quarter’s performance to delayed contract awards, technical setbacks in development programs, and the impact of the Edge Autonomy acquisition, while highlighting strategic diversification and new business initiatives.

• Government contract delays: Management emphasized that U.S. and international government budgeting delays pushed anticipated contract awards into later periods, directly impacting near-term revenue and project timelines.
• Technical and cost challenges: A single RF systems development contract experienced significant unforeseen technical complexity, resulting in unfavorable cost adjustments (EACs) and a notable reduction in profitability.
• Edge Autonomy acquisition impact: The integration of Edge Autonomy, a manufacturer of uncrewed aerial systems (UAS), diversified Redwire’s business mix and brought higher-margin production programs to offset exposure to volatile development contracts.
• Backlog and pipeline growth: Redwire reported a sequential increase in backlog, including nearly $90 million in contracts with point-in-time revenue recognition, and highlighted a robust pipeline of $11 billion in identified opportunities across space and airborne solutions.
• SpaceMD commercial launch: The company launched SpaceMD to commercialize microgravity pharmaceutical research, signing agreements with Aspera Biomedicines and ExesaLibero Pharma, aiming to generate new revenue streams through drug development partnerships and royalty agreements.

Drivers of Future Performance

Redwire’s outlook for the coming quarters hinges on ramping up production programs, navigating government budget cycles, and commercializing new lines of business.

• Shift toward production contracts: Management expects a growing share of revenue to come from mature, production-phase programs—especially following the Edge Autonomy acquisition—reducing exposure to cost volatility from development contracts and supporting margin stability.
• Government and defense spending trends: The company anticipates that increased U.S. and allied defense budgets, including new NATO and Canadian commitments, will drive demand for both space and airborne systems, but recognizes timing remains uncertain due to administrative delays.
• Commercialization of microgravity research: With the launch of SpaceMD, Redwire aims to establish recurring revenue from space-based pharmaceutical R&D, leveraging its PIL-BOX platform and new royalty agreements as a differentiated long-term growth engine.

Catalysts in Upcoming Quarters

In the upcoming quarters, StockStory’s analysts will watch (1) the pace at which Redwire converts its growing backlog into revenue, especially with new production contracts, (2) progress on integrating Edge Autonomy and realizing expected margin improvements, and (3) early revenue contributions and partnership growth from the SpaceMD venture. Ongoing developments in government funding cycles and contract awards will also be critical to track.

Redwire currently trades at $8.85, down from $13.70 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).

Stocks That Trumped Tariffs

Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.

The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.